PhRMA Vice President for International Policy Kevin Haninger prepared an oral statement for the March 30, 2023 U.S. International Trade Commission (USITC) hearing concerning its Section 332 investigation titled “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities.”